{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreie7eh66v4nxf7h5ugtyeut7m7inx5hkcxkuauc6o3spywtnobra3a",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mje355ndvf52"
  },
  "path": "/2026/04/13/anbogen-therapeutics-to-present-dual-breakthroughs-for-imofinostat-abt-301-at-aacr-2026-addressing-immunotherapy-barriers-in-crc-and-chemo-resistance-in-pancreatic-cancer/",
  "publishedAt": "2026-04-13T04:00:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "TAIPEI, April 13, 2026 /PRNewswire/ — AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate ABT-301’s superior performance in enhancing immunotherapy […]",
  "title": "AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer"
}